Apogee Therapeutics, Inc.
NASDAQApogee Therapeutics enters the week with a striking split between its price action and analyst sentiment — the stock has nearly doubled over the past month while the Street has systematically moved to the sidelines. The most dramatic data point is the collapse in short interest. Bears have retreated sharply: SI has fallen roughly 50% over the past month to 7.8% of the free float…
APGE cost to borrow surges to 1.14% — up 176% in one week — as short sellers face tightening availability.
Snapshot as of 26 Aug 2026
Apogee Therapeutics enters the week with a striking split between its price action and analyst sentiment — the stock has nearly doubled over the past month while the Street has systematically moved to the…
Apogee Therapeutics heads into the week with a freshly cut analyst rating colliding against a short position that has grown 18% in a month — the tension between a broadly bullish Street and a determined bear camp is…
Apogee Therapeutics reports today against a backdrop of distinctly defensive positioning — options markets are flashing the clearest caution signal seen in months, even as short sellers hold a structurally large stake…
Apogee Therapeutics enters its June 9 Q1 readout with the Street tilting constructive and short sellers trimming positions for the third consecutive month — an unusual alignment for a pre-revenue biotech trading at 16%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for APGE — free to start on ORTEX.
Sign up for free →Open APGE on ORTEX